keynote 564 | Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell

Keyword	CPC	PCC	Volume	Score	Length of keyword
keynote 564	0.11	0.7	4114	65	11
keynote	1.42	1	7326	89	7
564	0.51	0.3	7860	33	3

Keyword	CPC	PCC	Volume	Score
keynote 564	1.93	0.8	585	56
keynote 564 trial	0.36	0.5	2979	69
keynote 564 nejm	1.85	0.7	8820	72
keynote 564 overall survival	0.47	1	4051	67
keynote 564 update	0.45	0.4	3370	2
keynote 564 studie	0.96	0.6	2064	2
keynote 564 pembrolizumab	0.09	0.2	8709	50
keynote 564 study design	1.26	0.5	5722	15
keynote 564 inclusion criteria	1.06	0.2	2967	68
keynote 564 update 2023	0.79	1	4407	7
keynote 564 study	1.79	0.2	7917	97
keynote 564 results	2	0.2	7719	91
aso gu 2023 keynote 564	0.07	0.9	536	5

Search Results related to keynote 564 on Search Engine

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2106391

WebAug 18, 2021 · We conducted the KEYNOTE-564 trial to evaluate whether treatment with pembrolizumab after nephrectomy, with or without metastasectomy, would result in improved outcomes, as compared with...

DA: 1 PA: 49 MOZ Rank: 69

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2312695

Web3 days ago · After a median follow-up of 57.2 months, the KEYNOTE-564 trial showed a significant and a clinically meaningful improvement in overall survival with an adjuvant therapy in kidney cancer.

DA: 57 PA: 52 MOZ Rank: 12

KEYNOTE-564: Adjuvant Pembrolizumab Prolongs Survival in …
ascopubs.org

https://dailynews.ascopubs.org/do/keynote-564-adjuvant-pembrolizumab-prolongs-survival-high-risk-clear-cell-renal-cell

WebJan 27, 2024 · KEYNOTE-564 is the first trial to show statistically significant and clinically meaningful survival improvements with an adjuvant therapy in RCC. The results support adjuvant pembrolizumab as a standard of care after surgery for patients with ccRCC who are at higher risk for recurrence.

DA: 27 PA: 40 MOZ Rank: 30

KEYNOTE-564: Adjuvant immunotherapy for renal cell carcinoma
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796759/

WebJan 1, 2022 · Despite extensive research, no form of adjuvant therapy has shown a meaningful survival advantage or is practiced widely for this malignancy. KEYNOTE-564 was an international, phase three, randomized, double-blind trial involving patients with clear cell RCC at high risk for recurrence post nephrectomy. [ 2] The protocol defined the high …

DA: 97 PA: 69 MOZ Rank: 24

Overall survival results from the phase 3 KEYNOTE-564 study
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.LBA359

WebJan 29, 2024 · KEYNOTE-564 is the first phase 3 study to show improved survival with any adjuvant therapy in RCC. These results continue to support adjuvant pembrolizumab as a standard of care. Clinical trial information: NCT03142334.

DA: 48 PA: 27 MOZ Rank: 76

Pembrolizumab versus placebo as post-nephrectomy adjuvant
thelancet.com

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00487-9/fulltext

WebThe first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared with placebo after surgery in patients with clear cell renal cell carcinoma at an increased risk of recurrence.

DA: 21 PA: 22 MOZ Rank: 6

Adjuvant Pembrolizumab Offers Improved OS in KEYNOTE-564
targetedonc.com

https://www.targetedonc.com/view/adjuvant-pembrolizumab-offers-improved-os-in-keynote-564-trial-of-ccrcc

Web1 day ago · The landmark KEYNOTE-564 study is a double-blind, placebo-controlled trial which randomized patients with ccRCC with an increased risk of recurrence after surgery in a 1:1 fashion to receive 200 mg of pembrolizumab or placebo every 3 weeks for up to 17 cycles. 3 Treatment could also continue until recurrence, the occurrence of unacceptable ...

DA: 28 PA: 27 MOZ Rank: 38